Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

2.

Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.

Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A.

Ann Rheum Dis. 2012 Feb;71(2):198-205. doi: 10.1136/ard.2010.148700. Epub 2011 Sep 26.

3.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

PMID:
21542001
4.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3.

PMID:
19802508
5.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

PMID:
19567517
6.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators.

Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6.

PMID:
19362675
7.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators.

J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5.

PMID:
18682511
8.

Perspectives on the relationship of adrenal steroids to rheumatoid arthritis.

Masi AT, Chatterton RT, Aldag JC, Malamet RL.

Ann N Y Acad Sci. 2002 Jun;966:1-12. Review.

PMID:
12114253
9.

Heavy cigarette smoking and RA.

Masi AT, Aldag JC, Malamet RL.

Ann Rheum Dis. 2001 Dec;60(12):1154-5. No abstract available. Erratum in: Ann Rheum Dis 2002 Feb;61(2):189.

10.

Smoking and rheumatoid arthritis: comment on the letter by McDonagh and Walker.

Masi AT, Fecht T, Aldag JC, Malamet RL, Hazes JM.

Arthritis Rheum. 1998 Jan;41(1):184-5. No abstract available.

PMID:
9433888
11.

Serum concentrations of alpha tocopherol, beta carotene, and retinol preceding the diagnosis of rheumatoid arthritis and systemic lupus erythematosus.

Comstock GW, Burke AE, Hoffman SC, Helzlsouer KJ, Bendich A, Masi AT, Norkus EP, Malamet RL, Gershwin ME.

Ann Rheum Dis. 1997 May;56(5):323-5.

12.

Reproducibility of cold provocation in patients with Raynaud's phenomenon.

Wigley FM, Malamet R, Wise RA.

J Rheumatol. 1987 Aug;14(4):751-5.

PMID:
3668980
13.
14.

Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.

Wigley FM, Wise RA, Malamet R, Scott TE.

Arthritis Rheum. 1987 Mar;30(3):281-6.

PMID:
2952125
15.

Prostaglandins and estradiol-induced attenuation of hypoxic pulmonary vasoconstriction.

Sylvester JT, Gordon JB, Malamet RL, Wetzel RC.

Chest. 1985 Oct;88(4 Suppl):252S-254S.

PMID:
3840073
16.

Digital pressure-flow relationships in subjects with Raynaud's phenomenon.

Wise RA, Wigley FM, Malamet R.

Angiology. 1985 Sep;36(9):596-602.

PMID:
4051252
17.

Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation.

Malamet R, Wise RA, Ettinger WH, Wigley FM.

Am J Med. 1985 Apr;78(4):602-8.

PMID:
3157318
18.

A survey of osteoarthritis of the knee in the elderly.

Forman MD, Malamet R, Kaplan D.

J Rheumatol. 1983 Apr;10(2):282-7.

PMID:
6864681
19.

"Polymyositis"-like syndrome resulting from hypothyroidism in a patient with a nodular lymphoma.

Schnipper EF, Malamet RL, Arlin ZA.

Clin Bull. 1981;11(1):34-5. No abstract available.

PMID:
7023746
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk